3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
3
Withdrawn
2
Unknown
1
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Conditions
Thrombocythemia, Essential
1
Recurrence
1
Polycythemia Vera
1
Polycythemia
1
Ovarian Neoplasms
1
Neuroectodermal Tumors
1
Neuroblastoma
1
Neoplasms, Plasma Cell
1
Neoplasms
1
Multiple Myeloma
1
Leukemia, Myeloid, Acute
1
Hematologic Diseases
1
Carcinoma, Non-Small-Cell Lung
1
Breast Neoplasms
1
Interventions
Cyclophosphamide
16
Dexamethasone
14
Melphalan
12
Bortezomib
11
Filgrastim
6
Peripheral Blood Stem Cell Transplantation
5
Lenalidomide
5
Thalidomide
4
Prednisone
4
sargramostim
3
fludarabine phosphate
3
daratumumab
3
Radiotherapy
3
Mycophenolic Acid
3
Interferon-alpha
3
Doxorubicin
3
Busulfan
3
Antilymphocyte Serum
3
pomalidomide
2
isatuximab
2
fludarabine
2
Vincristine
2
Methylprednisolone
2
Idarubicin
2
Cyclosporine
2
Carmustine
2
plerixafor
1
pegfilgrastim
1
orantinib
1
epoetin beta
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Unknown
×
Neoplasms, Plasma Cell
×
Vorinostat
×
Clear all
NCT01554852
2018-06-11
Myeloma XI
University of Leeds
Phase 3
Unknown
4,420 enrolled